90-day analysis shows moderna's omicron ba.1-targeting bivalent vaccine, mrna-1273.214, demonstrates superior antibody response as fourth booster compared to spikevax prototype booster

Data indicate durable immune response from bivalent booster after three months of follow-up mrna-1273.214 also demonstrated potent response to omicron ba.2.75 cambridge, ma / accesswire / october 19, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced new clinical data on its bivalent omicron-containing booster, mrna-1273.214. ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 Μg booster dose of mrna-1273.214 elicited a superior neutralizing antibody response against omicron ba.1 when compared to a 50 Μg booster dose of mrna-1273 in all participants regardless of prior infection.
MRNA Ratings Summary
MRNA Quant Ranking